Literature DB >> 14976

Plasma level studies of penbutolol after oral dose in man.

J J Vallner, H W Jun, T E Needham, J T Stewart, W Brown, H Frazer, I L Honigberg.   

Abstract

Plasma levels of penbutolol (HOE 893d) were determined in eight healthy adult male subjects after oral administration of 50-mg capsules. Fast absorpiton of the drug from the gastrointestinal tract was indicated by the rapid increase in plasma levels during the absorption phase, with a peak time at about 1 hour after dosing in all subjects. After the peak level, plasma concentrations declined biexponentially, with an average half-life of 2.5 and 27 hours for the fast and slow disposition phases, respectively. These values were in good agreement with data previously found for this drug. Cumulative excretion of intact drug in the urine of the eight subjects during 72 hours after dosing was less than 4 per cent, except for one subject who excreted 9.82 per cent of the dose. Large individual variations were found for area under the plasma level curves, disposition rates, and amounts of intact drug excreted in the urine. Significant pharmacologic effects were noted in all eight subjects at the 50-mg dose level, and mild side effects were evident in one half of these subjects. The average drop in blood pressure and pulse rate for all subjects was 26/18 mm Hg and 19 beats per minute, respectively.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 14976     DOI: 10.1177/009127007701700407

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioligand binding.

Authors:  D Brockmeier; P Hajdù; W Henke; E Mutschler; D Palm; W Rupp; H Spahn; M T Verho; A Wellstein
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Pharmacokinetics of penbutolol and its metabolites in renal insufficiency.

Authors:  N Bernard; G Cuisinaud; N Pozet; P Y Zech; J Sassard
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Penbutolol: beta-adrenoceptor interaction and the time course of plasma concentrations explain its prolonged duration of action in man.

Authors:  A Wellstein; D Palm
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Penbutolol (Hoe 893d) in primary hypertension. Blood pressure effects, tolerance and plasma concentrations.

Authors:  K P Ohman; J Asplund; S Landahl; B Liander
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Penbutolol: a preliminary review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-07       Impact factor: 9.546

6.  Penbutolol Pharmacokinetics: the influence of concomitant administration of cimetidine.

Authors:  H Spahn; W Kirch; P Hajdu; E Mutschler; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Haemodynamic dose-response effects of i.v. penbutolol in angina pectoris.

Authors:  B Silke; S P Verma; M Hussain; G I Nelson; R C Okoli; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

8.  Penbutolol or hydrochlorothiazide once a day in hypertension. A controlled study with home measurements.

Authors:  J F De Plaen; E Vander Elst; C Van Ypersele de Strihou
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

Review 9.  Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches.

Authors:  Aikaterini Zisaki; Ljubisa Miskovic; Vassily Hatzimanikatis
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.